I8F-MC-GPHJ: A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities

The primary objective of this study is to demonstrate that **tirzepatide** at the maximum tolerated dose (MTD) is superior to **semaglutide** 2.4 mg in achieving a mean percent decrease in weight loss. This is clinically relevant as effective weight management is crucial for individuals with **obesity** or **overweight** and associated weight-related comorbidities, potentially reducing the risk of further health complications.

Secondary objectives include:

• Demonstrating that tirzepatide at MTD is superior to semaglutide 2.4 mg at Week 72 for body weight and waist circumference.
• Comparing tirzepatide MTD to semaglutide 2.4 mg at Week 72 for body weight and body mass index (BMI).

The clinical trial involves a total of **557 participants** who are being studied to evaluate the efficacy of tirzepatide compared to semaglutide 2.4 mg in achieving weight loss. The study population includes both **male and female** subjects, encompassing an age range that includes adults and older adults. Participants were selected based on their health status, specifically those with **obesity** or overweight individuals who also have at least one comorbid condition such as obstructive sleep apnea, high blood pressure, high cholesterol, or heart disease. The trial does not exclude vulnerable populations, indicating a diverse participant group. Lifestyle factors such as diet and physical activity are not specified, but the inclusion criteria suggest a focus on individuals with significant health concerns related to weight. The selection process ensures a representative sample of the target population for the study's objectives.

The clinical trial is designed as a **randomized**, **controlled** study to evaluate the efficacy and safety of **Tirzepatide** compared to **Semaglutide** in adults with **obesity** or **overweight** with weight-related comorbidities. The trial is conducted in a **double-blind** manner to ensure unbiased results. The primary objective is to demonstrate that Tirzepatide at the maximum tolerated dose (MTD) is superior to Semaglutide 2.4 mg in achieving a mean percent decrease in body weight. The trial is expected to last for approximately 72 weeks, with participant involvement spanning the same duration.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on criteria such as having obesity or being overweight with conditions like obstructive sleep apnea, high blood pressure, high cholesterol, or heart disease. Following the screening, participants will be randomized to receive either Tirzepatide or Semaglutide, both administered as a **solution for injection**. Regular follow-up visits will be scheduled to monitor progress, assess safety, and collect data on primary and secondary endpoints, including changes in body weight, waist circumference, and body mass index (BMI).

The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to evaluate the overall outcomes of the treatment. Participants may be withdrawn from the study early if they experience adverse effects, fail to comply with study procedures, or choose to discontinue participation. The trial's primary endpoint is the percent change from baseline in body weight, while secondary endpoints include the percentage of participants achieving significant weight reductions and changes in waist circumference and BMI.

The clinical trial involves the administration of **Tirzepatide**, a solution for injection, as the experimental medication. Tirzepatide, also known by its sponsor product code LY3298176, is developed by Eli Lilly and Company. The active substance, LY3298176, is a protein of other origin. The pharmaceutical form is a solution for injection, with a maximum daily dose of 2.14 mg and a maximum total dose of 1.08 g over a treatment period of 72 weeks. The administration route is subcutaneous injection. Participant compliance is monitored through regular assessments to ensure adherence to the dosing schedule.

**Semaglutide** serves as the comparator treatment in this study. It is also a solution for injection, with the active substance being a protein of other origin. The maximum daily dose for Semaglutide is 0.34 mg, with a maximum total dose of 172.8 mg over the same 72-week treatment period. The administration route is subcutaneous injection. As a comparator, Semaglutide is used to evaluate the efficacy and safety of Tirzepatide in comparison to an established treatment for obesity or overweight with weight-related comorbidities.

The efficacy of the clinical trial will be assessed by evaluating the primary and secondary endpoints. The primary endpoint is the **percent change from baseline in body weight**. Secondary endpoints include the percentage of participants who achieve ≥10%, ≥15%, ≥20%, and ≥25% body weight reduction, as well as changes from baseline in waist circumference and body mass index (BMI). These endpoints will be measured at specified time points throughout the trial duration, which is planned for a maximum treatment period of 72 weeks.

The trial involves a comparison between two investigational products: Tirzepatide and Semaglutide, both administered as a solution for injection. The efficacy assessments will be conducted using validated methods to ensure accuracy and reliability of the data collected. The analysis will focus on demonstrating that Tirzepatide at the maximum tolerated dose (MTD) is superior to Semaglutide 2.4 mg in achieving the primary endpoint of mean percent decrease in weight loss. The trial is designed to provide robust data on the efficacy of Tirzepatide in adults with obesity or overweight with weight-related comorbidities.